Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Self-propelled motion controlled by ionic liquids.
Hua E, Gao J, Xu Y, Matsuo M, Nakata S. Hua E, et al. Phys Chem Chem Phys. 2024 Mar 6;26(10):8488-8493. doi: 10.1039/d3cp05630a. Phys Chem Chem Phys. 2024. PMID: 38411193
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Among authors: hua e. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Cellular rejuvenation protects neurons from inflammation mediated cell death.
Drake SS, Mohammadnia A, Heale K, Groh AMR, Hua EM, Zaman A, Hintermayer MA, Zandee S, Gosselin D, Stratton JA, Sinclair DA, Fournier AE. Drake SS, et al. Among authors: hua em. bioRxiv [Preprint]. 2023 Oct 2:2023.09.30.560301. doi: 10.1101/2023.09.30.560301. bioRxiv. 2023. PMID: 37873446 Free PMC article. Preprint.
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Ji Y, Calonder C, Kirsilä T, Burciu A, Tisu M, Joubert Y, Laurent N, Hua E, Patekar M, Drollmann A, Woessner R. Ji Y, et al. Among authors: hua e. Pharmaceutics. 2023 Sep 1;15(9):2266. doi: 10.3390/pharmaceutics15092266. Pharmaceutics. 2023. PMID: 37765235 Free PMC article.
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M, Hua E, Ji Y, Burciu A, Savelieva M, Severin T, Drollmann A, Bienczak A. Staubach P, et al. Among authors: hua e. Pediatr Allergy Immunol. 2023 Jul;34(7):e13982. doi: 10.1111/pai.13982. Pediatr Allergy Immunol. 2023. PMID: 37492920 Clinical Trial.
91 results